BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Stephen Willey does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 NKTXNkarta Inc | Buy | $14.00 | Mar 2025 | +2.1% | Miss |
 VORVor Biopharma Inc | Buy | $5.00 | Mar 2025 | −28.4% | Miss |
 ABCLAbcellera Biologics Inc | Buy | $10.00 | Feb 2025 | +54.0% | Miss |
 GERNGeron Corporation | Buy | $4.00 | Feb 2025 | −14.0% | Miss |
 XFORX4 Pharmaceuticals Inc | Buy | $4.00 | Nov 2024 | −78.8% | Miss |
| ABCLAbcellera Biologics Inc | Buy | $12.00 | Nov 2024 | +69.8% | Miss |
 BCAXBicara Therapeutics Inc. Common Stock | Buy | $47.00 | Oct 2024 | −7.3% | Miss |
 CUECue Biopharma | Buy | $4.00 | Aug 2024 | −1.1% | Miss |
| GERNGeron Corporation | Buy | $7.00 | Jun 2024 | −62.8% | Miss |
| CUECue Biopharma | Buy | $8.00 | Apr 2024 | −60.2% | Miss |
| ABCLAbcellera Biologics Inc | Buy | $17.00 | Feb 2024 | −36.9% | Miss |
| CUECue Biopharma | Buy | $8.00 | Jun 2023 | −78.3% | Miss |
| XFORX4 Pharmaceuticals Inc | Buy | $5.00 | May 2023 | −64.1% | Miss |
| CUECue Biopharma | Buy | $8.00 | Mar 2023 | −59.1% | Miss |
 OABIOmniAb Inc. | Buy | $12.00 | Nov 2022 | +51.9% | Miss |
| CUECue Biopharma | Buy | $25.00 | Apr 2020 | −71.4% | Hit |
 ZYMEZymeworks Inc. Common Stock | Buy | $70.00 | Feb 2020 | −33.1% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.